Publicaciones en colaboración con investigadores/as de Karadeniz Technical University (23)

2022

  1. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

2017

  1. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276

  2. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, Núm. 3, pp. 196-203

  3. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1346-1357

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

2015

  1. BREMSO: A simple score to predict early the natural course of multiple sclerosis

    European Journal of Neurology, Vol. 22, Núm. 6, pp. 981-989

  2. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1159-1171

  3. Defining reliable disability outcomes in multiple sclerosis

    Brain, Vol. 138, Núm. 11, pp. 3287-3298

  4. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS

    PLoS ONE, Vol. 10, Núm. 6

  5. Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 1

  6. Predictors of disability worsening in clinically isolated syndrome

    Annals of Clinical and Translational Neurology, Vol. 2, Núm. 5, pp. 479-491

  7. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

    Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435

2014

  1. Predictors and dynamics of postpartum relapses in women with multiple sclerosis

    Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 739-746

  2. Risk of relapse phenotype recurrence in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 20, Núm. 11, pp. 1511-1522

  3. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

    Annals of Neurology, Vol. 76, Núm. 6, pp. 880-890

2013

  1. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

    PLoS ONE, Vol. 8, Núm. 5

  2. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

    Brain, Vol. 136, Núm. 12, pp. 3609-3617

2012

  1. Country, sex, edss change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

    PLoS ONE, Vol. 7, Núm. 6

  2. Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis

    PLoS ONE, Vol. 7, Núm. 10

  3. Increasing age at disability milestones among MS patients in the MSBase Registry

    Journal of the Neurological Sciences, Vol. 318, Núm. 1-2, pp. 94-99